The peroxisome proliferator-activated receptor gamma (PPARγ), which belongs to the family of nuclear receptors, has been mainly studied as an important factor in metabolic disorders. However, in recent years the potential role of PPARγ in different neurological diseases has been increasingly investigated. Especially, in the search of therapeutic targets for patients with epilepsy the question of the involvement of PPARγ in seizure control has been raised. Epilepsy is a chronic neurological disorder causing a major impact on the psychological, social, and economic conditions of patients and their families, besides the problems of the disease itself. Considering that the world prevalence of epilepsy ranges between 0.5% - 1.0%, this condition is the fourth for importance among the other neurological disorders, following migraine, stroke, and dementia. Among others, temporal lobe epilepsy (TLE) is the most common form of epilepsy in adult patients. About 65% of individuals who receive antiseizure medications (ASMs) experience seizure independence. For those in whom seizures still recur, investigating PPARγ could lead to the development of novel ASMs. This review focuses on the most important findings from recent investigations about the potential intracellular PPARγ-dependent processes behind different compounds that exhibited anti-seizure effects. Additionally, recent clinical investigations are discussed along with the promising results found for PPARγ agonists, and the ketogenic diet (KD) in various rodent models of epilepsy.

Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives / Senn, Lara; Costa, ANNA MARIA; Avallone, Rossella; Socała, Katarzyna; Wlaź, Piotr; Biagini, Giuseppe. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 241:(2023), pp. 1-17. [10.1016/j.pharmthera.2022.108316]

Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives

Lara Senn;Anna Maria Costa;Rossella Avallone;Giuseppe Biagini
2023

Abstract

The peroxisome proliferator-activated receptor gamma (PPARγ), which belongs to the family of nuclear receptors, has been mainly studied as an important factor in metabolic disorders. However, in recent years the potential role of PPARγ in different neurological diseases has been increasingly investigated. Especially, in the search of therapeutic targets for patients with epilepsy the question of the involvement of PPARγ in seizure control has been raised. Epilepsy is a chronic neurological disorder causing a major impact on the psychological, social, and economic conditions of patients and their families, besides the problems of the disease itself. Considering that the world prevalence of epilepsy ranges between 0.5% - 1.0%, this condition is the fourth for importance among the other neurological disorders, following migraine, stroke, and dementia. Among others, temporal lobe epilepsy (TLE) is the most common form of epilepsy in adult patients. About 65% of individuals who receive antiseizure medications (ASMs) experience seizure independence. For those in whom seizures still recur, investigating PPARγ could lead to the development of novel ASMs. This review focuses on the most important findings from recent investigations about the potential intracellular PPARγ-dependent processes behind different compounds that exhibited anti-seizure effects. Additionally, recent clinical investigations are discussed along with the promising results found for PPARγ agonists, and the ketogenic diet (KD) in various rodent models of epilepsy.
2023
24-nov-2022
241
1
17
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives / Senn, Lara; Costa, ANNA MARIA; Avallone, Rossella; Socała, Katarzyna; Wlaź, Piotr; Biagini, Giuseppe. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 241:(2023), pp. 1-17. [10.1016/j.pharmthera.2022.108316]
Senn, Lara; Costa, ANNA MARIA; Avallone, Rossella; Socała, Katarzyna; Wlaź, Piotr; Biagini, Giuseppe
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0163725822002108-main.pdf

Open Access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 2.11 MB
Formato Adobe PDF
2.11 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
PharmacolTherPPARgamma.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 721.5 kB
Formato Adobe PDF
721.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1291785
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact